PharmaEssentia Corp. (6446) AI Stock Analysis

PharmaEssentia Corp.

(TWSE:6446)

Select Model

Rating:81Outperform

Price Target:TWD 1,467.00▲(9.89% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is driven primarily by strong profitability, balance-sheet strength, and improving cash generation. Positive technical positioning adds support, while the high P/E ratio is the main constraint despite the attractive dividend yield.

Positive Factors

Revenue and Profitability ReboundThe sharp revenue acceleration and return to strong net profitability indicate meaningful improvement in commercial execution and operating scale. If maintained, this earnings base can support continued investment in the biologics portfolio, strengthen internal funding capacity, and improve long-term resilience.

Negative Factors

Historical Earnings VolatilityThe recent turnaround is encouraging, but the preceding period of heavy losses shows that profitability has not yet been demonstrated across a full operating cycle. A return of weaker results would reduce internally generated funding and make the current earnings profile less dependable for long-term planning.

PharmaEssentia Corp. (6446) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 543.83B
Dividend Yield: 0.11%
Average Volume (3M): 3.35M
Price to Earnings (P/E): 56.4
Beta (1Y): 0.66
Revenue Growth: 78.20%
EPS Growth: 87.80%
Country: TW
Employees: 342
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

PharmaEssentia Corp. Business Overview & Revenue Model

Company Description

PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the m...

PharmaEssentia Corp. Financial Statement Overview

Summary

Strong financial turnaround with excellent profitability, very low leverage, expanding equity, and positive free cash flow. Cash-flow conversion is weaker than earnings, and margins have not expanded materially.

Income Statement

88Very Positive

Balance Sheet

91Very Positive

Cash Flow

82Very Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	20.75B	15.63B	9.73B	5.11B	2.88B	656.51M
Gross Profit	18.64B	13.68B	8.56B	4.50B	2.07B	277.65M
EBITDA	9.38B	5.41B	3.38B	-671.49M	-1.60B	-2.57B
Net Income	7.63B	5.05B	2.97B	-623.84M	-1.37B	-2.81B
Balance Sheet
Total Assets	44.11B	37.41B	31.06B	27.27B	15.33B	6.20B
Cash, Cash Equivalents and Short-Term Investments	24.47B	22.72B	21.07B	19.67B	10.30B	3.45B
Total Debt	1.02B	856.06M	965.47M	1.20B	1.57B	536.31M
Total Liabilities	7.29B	5.44B	3.59B	3.32B	3.19B	1.95B
Stockholders Equity	36.82B	31.98B	27.47B	23.95B	12.14B	4.25B
Cash Flow
Free Cash Flow	5.94B	3.37B	1.64B	-2.03B	-1.83B	-2.56B
Operating Cash Flow	8.28B	5.28B	2.55B	-705.56M	-1.51B	-2.46B
Investing Cash Flow	-4.55B	-2.48B	-1.33B	-486.65M	-1.24B	-78.18M
Financing Cash Flow	-340.12M	-499.94M	-185.21M	10.45B	9.58B	2.81B

PharmaEssentia Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6446 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6446	81Outperform	TWD 528.07B	56.35	―	0.11%	78.20%	87.80%
TW:6472	60Neutral	TWD 50.12B	32.71	―	2.48%	-5.57%	-62.77%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6919	30Underperform	TWD 109.78B	-174.87	―	―	-54.34%	-24.43%

* General Sector Average

Performance Comparison

TW:6446 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6446	PharmaEssentia Corp.	1335.00	891.00	200.68%
TW:6472	Bora Pharmaceuticals Co Ltd	403.00	-209.62	-34.22%
TW:6696	Lin BioScience, Inc.	166.50	138.55	495.71%
TW:6919	Caliway Biopharmaceuticals Co Ltd	70.00	-57.00	-44.88%
TW:7799	Heron Neutron Medical Corp.	432.00	-178.00	-29.18%
TW:7924	TLC BioSciences Corp	402.50	192.00	91.21%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

PharmaEssentia Corp. AI Stock Analysis